Abstract 1290
Background
Pancreatic cancer (PC) is an aggressive disease with high lethality rate due to multiple resistance mechanisms. We used in vitro CRISPR/Cas9 genetic drop-out screening to identify genes involved in the regulation of PC cell line sensitivity to platinum chemotherapy drugs.
Methods
We used two sgRNA libraries: 1) enriched for genes regulating cell cycle and nuclear proteins genes (CC, 50 000 sgRNA targeting 4 716 genes); 2) genome-wide (GW, 90 000 sgRNA targeting 18 164 genes). We performed screens in MIA PaCa-2 cells expressing doxycycline-inducible Cas9. Cells were treated with established IC30 of oxaliplatin (1 uM) or cisplatin (3 uM) for 9 cell divisions (12 days). Genomic DNA was extracted and sgRNA-containing regions were amplified and barcoded by PCR for further analysis by NGS. Statistical analysis for sgRNA enrichment or depletion was performed using R package comparing cells treated with the drugs vs. vehicle in the presence of Cas9/doxycycline.
Results
We identified 755 genes which significantly changed in cisplatin or oxaliplatin-treated cells (FDR 5%, p < 0.05). Candidate genes (n = 130) were further selected if at least 2 sgRNA per gene showed more than 2-fold change vs. vehicle. Among the 130 genes, 16 were known platinum sensitivity regulators involved in the double stranded break DNA repair pathway; 11 genes were positive platinum sensitivity regulators as their inactivation reduced sensitivity; 119 genes were negative platinum sensitivity regulators as their inactivation increased sensitivity. Gene Ontology analysis of the 130 candidate genes allowed us to identify regulators of cell cycle (n = 46), DNA replication and repair (n = 43), cellular compromise (n = 15), cellular assembly and organization (n = 35) and cell morphology (n = 48). Analysis of protein-protein interaction network showed that the majority of the hits (n = 74) are directly involved into cell cycle regulation and DNA repair processes.
Conclusions
We identified 130 candidate genes potentially involved in the modulation of platinum resistance most of which are regulating the cell cycle and DNA repair which is in keeping with the known DNA damaging mechanisms of action of platinum chemotherapy.
Clinical trial identification
Legal entity responsible for the study
Kazan Federal University.
Funding
The work is performed according to the Russian Government Program of Competitive Growth of Kazan Federal University.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - TCR beta chain convergence defines the tumor infiltrating T cell repertoire of melanoma and non-small cell lung carcinoma.
Presenter: Timothy Looney
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3212 - PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Presenter: Ahmad Awada
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3574 - Pan-squamous genomic profiling stratified by anatomic tumor site and viral association
Presenter: Meagan Montesion
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4113 - Toward the Standardization of Bioinformatics Methods for the Accurate Assessment of Tumor Mutational Burden (TMB)
Presenter: Han Chang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4468 - Prediction of primary resistance to anti-PD1 therapy (APD1) in 2nd line NSCLC
Presenter: Egbert Smit
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4570 - Immunomodulatory germline variation impacts the development of multiple primary melanoma (MPM).
Presenter: Robert Ferguson
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1169 - Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
Presenter: Ming Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1707 - Gene embedding: a novel machine learning approach to identify gene candidates related to immunotherapy responsiveness
Presenter: Chi Tung Choy
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2123 - Common and rare DPYD variants are predictive for 5FU/capecitabine (5FU) toxicity: The MRC COIN and COIN-B trials
Presenter: Ayman Madi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5671 - The landscape of NTRK fusions in Chinese solid tumor patients
Presenter: Qi Ling
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract